Effect of Treatment with GnRH Agonists on New Markers of Bone Metabolism
This study found that urinary N-telopeptides increased by 44% and bone-specific alkaline phosphatase increased by 40% after 3 months of GnRH agonist treatment in women, indicating increased bone resorption and formation.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (11)
- Bone loss during gonadotropin releasing hormone agonist treatment and use of nasal calcitonin via openalex
- Excretion of urinary n-telopeptides reflects changes in bone turnover during ovarian suppression and indicates individually variable estradiol threshold for bone loss via openalex
- Gonadotropin releasing hormone agonist therapy and its effect on bone mass via openalex
- Treatment of Endometriosis with the Luteinizing Hormone-Releasing Hormone Agonist Nafarelin. Effect on Bone Turnover and Bone Mass via openalex
- Urinary N-Telopeptides to Monitor Bone Resorption While on GnRH Agonist Therapy via openalex
- W2062982521 via openalex
- W2078249213 via openalex
- W2115941653 via openalex
- W2027858461 via openalex
- W2013079995 via openalex
- W2059516397 via openalex
Cited by (1)
Source provenance
- europepmc
- last seen: 2026-09-03T06:15:13.668130+00:00
- openalex
- last seen: 2026-06-04T00:00:01.174412+00:00
- pubmed
- last seen: 2026-05-13T22:10:29.640636+00:00
- unpaywall
- last seen: 2026-09-03T06:36:50.994332+00:00